Stock Analysis on Net

CVS Health Corp. (NYSE:CVS)

Enterprise Value to EBITDA (EV/EBITDA)

Microsoft Excel

Earnings before Interest, Tax, Depreciation and Amortization (EBITDA)

CVS Health Corp., EBITDA calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Net income attributable to CVS Health 4,614 8,344 4,149 7,910 7,179
Add: Net income attributable to noncontrolling interest (28) 24 16 (12) 13
Less: Loss from discontinued operations, net of tax (9)
Add: Income tax expense 1,562 2,805 1,463 2,522 2,569
Earnings before tax (EBT) 6,148 11,173 5,628 10,420 9,770
Add: Interest expense 2,958 2,658 2,287 2,503 2,907
Earnings before interest and tax (EBIT) 9,106 13,831 7,915 12,923 12,677
Add: Depreciation and amortization 4,597 4,366 4,247 4,512 4,441
Earnings before interest, tax, depreciation and amortization (EBITDA) 13,703 18,197 12,162 17,435 17,118

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Item Description The company
EBITDA To calculate EBITDA analysts start with net earnings. To that earnings number, interest, taxes, depreciation, and amortization are added. EBITDA as a pre-interest number is a flow to all providers of capital. CVS Health Corp. EBITDA increased from 2022 to 2023 but then slightly decreased from 2023 to 2024 not reaching 2022 level.

Enterprise Value to EBITDA Ratio, Current

CVS Health Corp., current EV/EBITDA calculation, comparison to benchmarks

Microsoft Excel
Selected Financial Data (US$ in millions)
Enterprise value (EV) 141,156
Earnings before interest, tax, depreciation and amortization (EBITDA) 13,703
Valuation Ratio
EV/EBITDA 10.30
Benchmarks
EV/EBITDA, Competitors1
Abbott Laboratories 21.76
Cigna Group 12.00
Elevance Health Inc. 9.07
Intuitive Surgical Inc. 55.21
Medtronic PLC 15.94
UnitedHealth Group Inc. 18.95
EV/EBITDA, Sector
Health Care Equipment & Services 16.93
EV/EBITDA, Industry
Health Care 19.81

Based on: 10-K (reporting date: 2024-12-31).

1 Click competitor name to see calculations.

If the company EV/EBITDA is lower then the EV/EBITDA of benchmark then company is relatively undervalued.
Otherwise, if the company EV/EBITDA is higher then the EV/EBITDA of benchmark then company is relatively overvalued.


Enterprise Value to EBITDA Ratio, Historical

CVS Health Corp., historical EV/EBITDA calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in millions)
Enterprise value (EV)1 135,154 146,035 151,066 181,495 146,595
Earnings before interest, tax, depreciation and amortization (EBITDA)2 13,703 18,197 12,162 17,435 17,118
Valuation Ratio
EV/EBITDA3 9.86 8.03 12.42 10.41 8.56
Benchmarks
EV/EBITDA, Competitors4
Abbott Laboratories 22.28 19.49 15.85 17.42 25.99
Cigna Group 11.20 12.11 8.88 9.06 6.31
Elevance Health Inc. 8.15 10.24 10.26 10.05 7.57
Intuitive Surgical Inc. 63.79 53.82 41.52 44.54 59.12
Medtronic PLC 14.63 15.28 14.99 24.41 17.92
UnitedHealth Group Inc. 17.17 13.60 15.11 17.39 13.39
EV/EBITDA, Sector
Health Care Equipment & Services 16.32 13.82 13.98 15.40 13.12
EV/EBITDA, Industry
Health Care 19.95 18.98 13.71 13.87 16.50

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 See details »

2 See details »

3 2024 Calculation
EV/EBITDA = EV ÷ EBITDA
= 135,154 ÷ 13,703 = 9.86

4 Click competitor name to see calculations.

Valuation ratio Description The company
EV/EBITDA Enterprise value to earnings before interest, tax, depreciation and amortization is a valuation indicator for the overall company rather than common stock. CVS Health Corp. EV/EBITDA ratio decreased from 2022 to 2023 but then slightly increased from 2023 to 2024.